Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK shares analysts get out the red pens after FDA knock-back wipes £3bn from drug maker's value
08:38am, Friday, 18'th Jul 2025
Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell 6% on Thursday, wiping more than £3bn from its market value, after a US advisory committee delivered a serious blow to the drugmaker's oncology ambitions.
GSK shares slide 6% after US panel rejects key cancer drug combination
05:16am, Friday, 18'th Jul 2025
GSK PLC (LSE:GSK, NYSE:GSK) shares dropped 6% on Friday, erasing over £3 billion from its market value, after a panel of experts advising the US Food and Drug Administration voted against the compan
GSK shares fall after blood cancer drug likely headed for U.S. rejection
03:24am, Friday, 18'th Jul 2025
GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over eye-related side effects.
GSK gets red light from FDA cancer committee on Blenrep combos
02:49am, Friday, 18'th Jul 2025
An expert panel advising the US drug regulator has voted against GSK PLC's (LSE:GSK, NYSE:GSK) Blenrep drug combinations for patients with relapsed or refractory multiple myeloma. The US Food and Dr
FDA Committee Votes Against GSK Blood Cancer Drug Blenrep
06:19pm, Thursday, 17'th Jul 2025
The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or refractory multiple myeloma who have previously received at least one line of therap
Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an exis
FDA advisers vote against combination therapies of GSK's blood cancer drug
12:53pm, Thursday, 17'th Jul 2025
The U.S. Food and Drug Administration's panel of independent advisers voted on Thursday against approval of GSK's blood cancer drug Blenrep for use in combination with other treatments.
US FDA approves pre-filled version of GSK's shingles vaccine
07:35am, Thursday, 17'th Jul 2025
The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, providing patients a more convenient option to receive the shot, the company
US FDA Approves GSK's SHINGRIX in a Prefilled Syringe Presentation
07:00am, Thursday, 17'th Jul 2025
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of SHINGRIX (Zoster Vaccine
FDA staff raises eye damage concerns for GSK's blood cancer drug
08:51am, Tuesday, 15'th Jul 2025
The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
11:16am, Monday, 14'th Jul 2025
FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.
GSK seeks FDA nod for expanded use of RSV vaccine in adults
02:42am, Monday, 14'th Jul 2025
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the age
GSK begins shipping influenza vaccine doses for the 2025-26 flu season
09:13am, Thursday, 10'th Jul 2025
PHILADELPHIA--(BUSINESS WIRE)--GSK begins shipping influenza vaccine doses for the 2025-26 flu season.
GSK's Specialty Medicines Unit on a Strong Footing: Here's Why
10:20am, Wednesday, 09'th Jul 2025
GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.
GSK's Specialty Medicines Surge - Still Looks Undervalued In 2025
07:45am, Monday, 07'th Jul 2025
GSK specialty medicines grew YoY in Q1 2025. In fact, it's now their main profit engine, offsetting the weakness in their vaccine segment. Similarly, the company's oncology, HIV, and respiratory biolo
